Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

BACKGROUND: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. The objective of this study was to assess the safety and efficacy of third-line anlotinib for patients with refractory advanced non-small-cell lung cancer (RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Baohui, Li, Kai, Zhao, Yizhuo, Li, Baolan, Cheng, Ying, Zhou, Jianying, Lu, You, Shi, Yuankai, Wang, Zhehai, Jiang, Liyan, Luo, Yi, Zhang, Yiping, Huang, Cheng, Li, Qiang, Wu, Guoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846072/
https://www.ncbi.nlm.nih.gov/pubmed/29438373
http://dx.doi.org/10.1038/bjc.2017.478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846072/
https://www.ncbi.nlm.nih.gov/pubmed/29438373
http://dx.doi.org/10.1038/bjc.2017.478

Ejemplares similares